ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment.

Santiago PonceSusana CedrésCharles RicordelNicolas IsambertSantiago ViteriMercedes Herrera-JuarezAlex Martinez-MartiAlejandro NavarroMathieu LederlinXavier SerresJon ZugazagoitiaSylvia VetrhusMagnus JaderbergThomas Birkballe HansenVictor LevitskyLuis Paz-Ares

Published in: Journal for immunotherapy of cancer (2023)

ONCOS-102 plus pemetrexed and cisplatin/carboplatin was well tolerated by patients with MPM. In injected tumors, ONCOS-102 promoted a proinflammatory environment, including T-cell infiltration, which showed association with survival at month 18.

Keyphrases

small cell lung cancer
advanced non small cell lung cancer
open label
phase ii study
randomized controlled trial
clinical trial
phase iii
double blind
radiation therapy
tyrosine kinase
study protocol